LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT has been awarded a $3.5M grant from the U.S. Department of Defense (DoD), U.S. Army Medical Research and Materiel Command (USAMRMC) (Fort Detrick, Md.). The grant supports two collaborative, clinical trials being conducted in the United States and Europe that are investigating a pathogen reduction technology for whole blood. Terumo BCT’s Mirasol System for Whole Blood is being evaluated for its potential to reduce the risk of infectious disease transmission and leukocyte-related transfusion reactions. The grant also supports pre-clinical work that will be performed to evaluate platelet and plasma function in vitro and in vivo, as well as studies of parasite reduction.
